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Abstract
Background: Translocations of the Mixed Lineage Leukemia (MLL) gene occur in a subset (5%) of acute
myeloid leukemias (AML), and in mixed phenotype acute leukemias in infancy - a disease with extremely
poor prognosis. Animal model systems show that MLL gain of function mutations may contribute to
leukemogenesis. Wild-type (wt) MLL possesses histone methyltransferase activity and functions at the level
of chromatin organization by affecting the expression of specific target genes. While numerous MLL fusion
proteins exert a diverse array of functions, they ultimately serve to induce transcription of specific genes.
Hence, acute lymphoblastic leukemias (ALL) with MLL mutations (MLLmu) exhibit characteristic gene
expression profiles including high-level expression of HOXA cluster genes. Here, we aimed to relate MLL
mutational status and tumor suppressor gene (TSG) methylation/expression in acute leukemia cell lines.
Results: Using MS-MLPA (methylation-specific multiplex ligation-dependent probe amplification assay),
methylation of 24 different TSG was analyzed in 28 MLLmu and MLLwt acute leukemia cell lines. On
average, 1.8/24 TSG were methylated in MLLmu AML cells, while 6.2/24 TSG were methylated in MLLwt
AML cells. Hypomethylation and expression of the TSG BEX2, IGSF4 and  TIMP3  turned out to be
characteristic of MLLmu AML cell lines. MLLwt AML cell lines displayed hypermethylated TSG promoters
resulting in transcriptional silencing. Demethylating agents and inhibitors of histone deacetylases restored
expression of BEX2, IGSF4 and TIMP3, confirming epigenetic silencing of these genes in MLLwt cells. The
positive correlation between MLL translocation, TSG hypomethylation and expression suggested that MLL
fusion proteins were responsible for dysregulation of TSG expression in MLLmu cells. This concept was
supported by our observation that Bex2 mRNA levels in MLL-ENL transgenic mouse cell lines required
expression of the MLL fusion gene.
Conclusion: These results suggest that the conspicuous expression of the TSG BEX2, IGSF4 and TIMP3
in MLLmu AML cell lines is the consequence of altered epigenetic properties of MLL fusion proteins.
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Background
Translocations of the Mixed Lineage Leukemia (MLL) gene
occur in a subset of acute leukemias. The correlation
between  MLL  translocations and expression of specific
gene clusters is so evident that "mixed lineage leukemia",
originally applied to biphenotypic acute leukemia cells, is
now used to describe the MLL mutant (MLLmu) acute
leukemias [1]. High expression levels of a set of HOXA
cluster genes are characteristic of MLL mutations in pri-
mary acute lymphoblastic leukemia (ALL) cells, and in
MLLmu ALL cell lines [1,2]. For acute myeloid leukemia
(AML) cell lines, a similar correlation exists between MLL
translocations and expression of the gene brain expressed
X-linked 2 (BEX2, formerly called BEX1) [3]. In healthy
people, BEX2 is expressed in the brain and, more weakly,
in pancreas and testis, but not in hematopoetic cells [3,4].
In leukemia cell lines, we found BEX2 expression to be
restricted to MLLmu AML. MLL wild-type (MLLwt) AML
and ALL cell lines and, notably, also MLLmu ALL cell lines
do not transcribe this gene, suggesting that BEX2 expres-
sion might be a diagnostic marker for MLLmu AML [3].
Several lines of evidence indicate that epigenetic mecha-
nisms are responsible for the regulation of BEX2 expres-
sion: (i) the BEX2 promoter is methylated in MLLwt and
unmethylated in MLLmu AML cell lines, thus demonstrat-
ing an inverse correlation between gene expression and
promoter methylation [5]; (ii) demethylating agents and
inhibitors of histone deacetylases (HDAC) induce BEX2
expression in MLLwt cells [5]; (iii) chromatin immuno-
precipitation experiments show that histone acetylation
plays a role in BEX2 regulation: immunoprecipitation of
acetylated histone H3 coprecipitates chromatin from the
5' region of BEX2 in MLLmu, but not in MLLwt cells [5].
BEX1 and BEX2 have recently been described as epigenet-
ically controlled candidate tumor suppressor genes (TSG)
in malignant glioma [6]. Promoter hypermethylation of
TSG is often seen in malignant diseases and, according to
a widely held view, contributes to the rise of malignant
cell clones by restraining tumor suppressor gene expres-
sion [7]. Moreover, unique profiles of hypermethylated
CpG islands have been described which are characteristic
of different neoplasias [8,9].
We applied a multiplex methylation detection assay to
find out whether the connection between the MLL muta-
tional status and promoter methylation is unique to BEX2
or if this correlation applies to other TSG as well. Results
show that MLLwt AML cell lines exhibit a higher propen-
sity for TSG promoter hypermethylation than MLLmu cell
lines. This is especially true for Immunoglobulin superfamily
member 4 (IGSF4/CADM1), Retinoic acid receptor beta
(RARB) and Tissue inhibitor of matrix metalloproteinase 3
(TIMP3), all with MLL-dependent methylation profiles
resembling BEX2. According to methylation-specific PCR
(MSP), primary AML cells without rearrangement of the
MLL gene also show a preference for TSG hypermethyla-
tion.
Our experimental results suggest that MLLmu proteins
enhance the expression of distinct TSG and that this might
be the consequence of altered epigenetic regulatory mech-
anisms of the fusion proteins.
Results and Discussion
Methylation patterns of TSG differ in MLLmu and MLLwt 
cell lines
Hypermethylation of CpG islands in the promoter regions
of TSG occurs widely in malignancy, resulting in transcrip-
tional inactivation which promotes cancerogenesis [7].
Unique profiles of hypermethylated CpG islands have
been described, being characteristic of different neopla-
sias [8,9]. BEX2  is a newly described TSG, which is
silenced by hypermethylation in malignant glioma [6].
With leukemia/lymphoma cell lines as model systems, we
have shown that BEX2 hypomethylation and gene expres-
sion typifies MLLmu AML [3]. BEX2 silencing in MLLwt
cells is the result of epigenetic mechanisms like promoter
methylation and histone deacetylation [3,5]. Here, we set
out to elucidate whether the described correlation
between promoter hypomethylation and genetically rear-
ranged MLL is peculiar to BEX2, or whether other TSG dis-
play similar features.
Methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA) was performed to assess the
methylation status of 24 TSG in 28 acute leukemia cell
lines, 50% with MLL translocations (see Additional file
1). ALL-derived cell lines showed a higher percentage of
methylated TSG than AML cell lines (Fig. 1). The mean
number of methylated TSG in ALL cell lines was inde-
pendent of MLL mutational status (Fig. 1). In contrast,
25% of all TSG analyzed were methylated in MLLwt, but
only 7% in MLLmu AML cell lines (Fig. 1). Provided that
the TSG tested are representative, MLLmu AML cell lines
display a significantly lower tendency to TSG hypermeth-
ylation than MLLwt cell lines.
Methylation status of BEX2, IGSF4, RARB and TIMP3 is 
indicative of MLLmu AML
Expression array analysis allows classification of tumors,
including the discrimination of acute leukemias with/
without MLL translocations [1]. Likewise, profiles of pro-
moter hypermethylation are unique for different types of
cancer and have also been used to identify lymphomatous
entities [8-12]. We evaluated our MS-MLPA data to find
out whether MLLmu and MLLwt cell lines could be distin-
guished via their respective TSG methylation patterns (see
Additional file 1). In addition to the 24 TSG included inMolecular Cancer 2009, 8:86 http://www.molecular-cancer.com/content/8/1/86
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this assay, we tested methylation of BEX2 by a methyla-
tion-sensitive DNA restriction- and quantitative real-time
PCR-assay.
Promoter methylation of TSG BEX2, IGSF4, RARB  and
TIMP3  distinguished  MLLmu and MLLwt AML: 0/7
MLLmu and 6/7 MLLwt AML cell lines exhibited methyl-
ation of at least two of these four TSG (p-value = 0.002,
Fisher's exact test) (Fig. 2). Neither these four genes nor
any other set of TSG analyzed distinguished between
MLLmu and MLLwt ALL cell lines, suggesting that a mye-
loid gene expression background was obligatory for the
MLL-specific methylation pattern (see Fig. 2, Additional
file 1).
Most of the 24 TSG analyzed did not allow the histologi-
cal origin of the cells to be inferred, being either methyl-
ated (e.g. ESR1) or unmethylated (e.g. BRCA2) in the
majority of cell lines (see Fig. 2, Additional file 1). Fur-
thermore, deletions, notably those of the TSG CDKN2A
and CDKN2B, occurred in ALL as well as in AML cell lines
(see Additional file 1). However, the methylation pattern
of three genes (DAPK1, FHIT, TP73) was highly character-
istic (p-values = 0.01, Fisher's exact test) of either ALL or
AML (Fig. 2). These results show that analysis of TSG
methylation may also be used to recognize distinct leuke-
mic entities. Noteworthy in the context of our study,
methylation patterns of BEX2, IGSF4, RARB and TIMP3
allowed discrimination between MLLmu and wt AML cell
lines (Fig. 2).
MS-MLPA is a screening technique and obtained results
rely on the analysis of one single CpG-site in the promoter
region. To verify the validity of the methylation status as
determined by MS-MLPA or HhaI-restriction-sensitive
PCR assay (for BEX2), we performed MSP after bisulfite
conversion of DNA for BEX2, IGSF4 and TIMP3 (see Addi-
tional file 2). The respective CpGs tested by MSP and MS-
MLPA were located at different promoter sites. The accu-
racy of MS-MLPA/HhaI-restriction-sensitive PCR to pre-
dict the methylation status of these three TSG as
determined by MSP was reassuringly high (83%), sup-
porting the validity of MS-MLPA for use in our screening.
In conclusion, most MLLwt cell lines show hypermethyl-
ation of BEX2, IGSF4 and TIMP3, while MLLmu cell lines
are preferentially unmethylated.
Methylation of tumor suppressor genes in primary MLLmu 
and MLLwt AML cells
CpG island hypermethylation occurs more often in cell
lines than in primary tumor cells [11,13]. Controversial
opinions exist on the question whether or not cell lines,
including leukemia cell lines, show the same methylation
profiles as the analogous primary cells [13-15]. To inves-
tigate the possible concordance of TSG methylation in cell
lines and primary cells, we tested samples from MLLmu
and MLLwt AML patients for TSG methylation. MS-MLPA
assay detected low numbers of methylated TSG (mean
0.5/24 +/- 1.0 TSG) in primary AML cells, which is in
accordance with earlier findings applying the same tech-
nique [16]. MSP has been shown to be a suitable and
more sensitive technique for primary AML samples than
MS-MLPA [17].
Therefore, we performed MSP after bisulfite conversion of
DNA and detected methylated and unmethylated TSG
promoter sequences using primers specific for BEX2,
IGSF4, RARB and TIMP3, the most informative genes in
our system (Fig. 3). For BEX2, IGSF4 and TIMP3, MSP
indicated a trend towards an association between pro-
moter methylation and MLLwt status (see Fig. 3B and
Additional file 3). This correlation could not be observed
for  RARB, rendering this gene less interesting for our
study. Bisulfite sequencing of the IGSF4 promoter region
confirmed MSP results: MLLwt AML patients (#9, #14 and
#15) and MLLwt cell line U-937 harbored clones with
CpG methylation adjacent to the transcriptional start site
of IGSF4, unlike MLLmu patient #23 and cell line THP-1
(see Fig. 4, Additional file 3).
Using methylation of at least two out of the three relevant
genes (BEX2, IGSF4 and TIMP3) as classifier for the MLL
Low tendency for TSG methylation in MLL mu AML cell lines Figure 1
Low tendency for TSG methylation in MLL mu AML 
cell lines. Methylation status of 24 TSG was determined by 
MS-MLPA (see also: Additional file 1). Mean numbers of 
methylated TSG and standard deviations in the different 
groups of leukemia cell lines are shown. Note that MLLmu 
AML, but not MLLmu ALL cell lines show reduced TSG 
methylation.
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mutational status, the true positive identification rate
(sensitivity) for MLLmu samples was 73%, with a specifi-
city of 58%, supporting the conclusion that methylation
of BEX2, IGSF4 and TIMP3 is more frequent in MLLwt
than in MLLmu patients (Fig. 3C). Testing a larger cohort
of patients will be necessary to confirm a statistically sig-
nificant positive correlation between MLL mutational sta-
tus and TSG methylation.
Inverse correlation of TSG methylation and expression
Hypermethylation of CpG islands in the promoter regions
of TSG generally leads to the silencing of the respective
genes [18,19]. To test whether BEX2, IGSF4, RARB and
TIMP3 were epigenetically regulated, we analyzed mRNA
expression of these genes in cell lines by quantitative real-
time PCR. Figure 5 shows that three of the four genes ana-
lyzed (BEX2, IGSF4 and TIMP3) demonstrated an inverse
correlation between TSG promoter methylation and gene
expression consistent with epigenetic gene regulation.
Predictive value for true methylation of these genes was
0.93, and accuracy 0.94. In contrast, RARB  remained
silent in most cell lines, independent of methylation sta-
tus (Fig. 5). A similar result has been described for RARA:
primary AML cells show low RARA2 expression although
the promoter is not methylated confirming that regula-
tion of gene transcription is a multi-factor process, not
solely reliant on promoter methylation/demethylation
[20]. Thus, (i) MLLmu AML cell lines express higher levels
of BEX2, IGSF4 and TIMP3 than MLLwt cell lines, and (ii)
these three TSG appear to be regulated by epigenetic
mechanisms.
RARB was excluded from further studies, as we neither
observed an inverse correlation between RARB promoter
methylation and gene expression in cell lines nor did we
see a positive correlation between MLLmu and RARB
hypomethylation in primary AML cells.
According to our findings, TSG hypomethylation and
mRNA expression are characteristic features of MLLmu
AML cells. This is in apparent conflict with the notion that
MLL fusion proteins act as strong oncogenes, a view that
is supported by the fact that MLLmu confers a dismal
prognosis in AML. We hypothesize that BEX2, IGSF4 and
TIMP3 are sentinel MLL fusion gene targets, their function
being overridden by the strong oncogene MLLmu. A better
understanding of how MLL fusion proteins impede TSG
TSG methylation predictive for classification of acute leukemia cell lines Figure 2
TSG methylation predictive for classification of acute leukemia cell lines. Methylation was assessed by MS-MLPA 
(see also Additional file 1) or by DNA digestion with methylation-sensitive HhaI plus promoter-specific quantitative real-time 
PCR (for analysis of BEX2). Green: methylation level ≥ 10%; yellow: methylation level < 10%. BEX2, IGSF4, RARB and TIMP3 are 
methylated in ALL and in MLLwt AML, but not in MLLmu AML. This correlation is statistically significant with p-values < 0.05 
for BEX2, RARB and TIMP3 and with a p-value of 0.051 for IGSF4 (Fisher's exact test). Methylation analysis of DAPK1, FHIT and 
TP73 discriminates between ALL and AML cell lines (p-values ≤ 0.01, Fisher's exact test). Other TSG (e.g. BRCA2 and ESR1) are 
methylated or unmethylated in the majority of cell lines with no preference for subtype.
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promoter methylation might help to illuminate a novel
epigenetic role for MLLmu in leukemic cells.
DNA demethylation and histone acetylation induce 
expression of TSG
To verify epigenetic regulation of BEX2, IGSF4 and TIMP3,
we applied the DNA-demethylating agent 5-Aza-2'-deoxy-
cytidine (Aza) and the HDAC inhibitor trichostatin A
(TSA). Our previous results had shown that these agents
induced expression of BEX2 in MLLwt AML cell lines [5].
We show here that Aza and TSA also triggered mRNA
expression of IGSF4 and TIMP3  (Table 1). To confirm
activity of TSA, histone H4K12 acetylation, a modification
associated with active transcription, was analyzed (see
Additional file 4). These results confirmed that epigenetic
mechanisms are responsible for TSG silencing in MLLwt
cell lines and suggest that TSG hypomethylation in
MLLmu cell lines might be caused by alterations of epige-
netic MLL functions as result of the various translocations.
Bex2 transcription depends on expression of MLL-ENL
To verify whether MLL fusion proteins were responsible
for altered expression of TSG, we applied a mouse bone
marrow cell line system that expresses MLL-ENL fused to
the ligand-binding domain of the estrogen receptor.
Removal of 4-hydroxytamoxifen (4-OHT) from the
medium tethers MLL-ENL to a heat shock protein com-
plex, thereby blocking the activation of the fusion protein
[21]. Withdrawal of 4-OHT led to a marked decrease of
Bex2 expression in this mouse cell system confirming that
MLL fusion proteins serve to upregulate this gene (Fig. 6).
These results suggest that expression of TSG in MLLmu
cell lines is attributable to the presence of MLL fusion pro-
teins, raising the question whether the MLL fusion pro-
teins directly target TSG promoters by blocking DNA
methylation processes, or whether these effects are sec-
ondary.
It is difficult to attribute a specific oncogenic function to
any single region of MLL fusion genes. Characteristic of
the complexity of the situation is that many MLL translo-
cations are reciprocal, and that both fusion genes are tran-
scribed and may function oncogenically. However, MLL-
ENL alone was sufficient to induce Bex2 in the transgene
system indicating that the reciprocal fusion product was
not required for regulation of this TSG. Furthermore, we
observed TSG hypomethylation in various MLLmu cell
lines with a variety of fusion partners. Together, these
observations suggested that the inhibitory effect of MLL
fusion genes on TSG promoter methylation was mediated
by the N-terminal part of MLL and not by the fusion part-
ner.
Both, the N-terminal and the C-terminal part of MLL have
been implicated in transcriptional and/or epigenetic regu-
lation. Located 3', the Su(var)3-9, enhancer-of-zeste,
trithorax (SET) domain confers histone H3K4 methyl-
transferase activity to the protein [22]. However, histone
H3K4 methylation is a marker for epigenetic activation
and it appears unlikely that the loss of an activating func-
tion should lead to expression of TSG. Located upstream
of the MLL breakpoint cluster region and retained in MLL
fusion genes is the CXXC DNA methyltransferase homol-
TSG methylation in primary AML samples Figure 3
TSG methylation in primary AML samples. Methyla-
tion status was assessed by MSP for BEX2, IGSF4, TIMP3 and 
RARB in a panel of MLLwt and MLLmu AML patients. A) Rep-
resentative results for BEX2 MSP are shown. Patients #1 - 
#17 carry MLLwt, patients #18 - #40 harbor MLL rearrange-
ments (see Additional file 3). B) Summary of methylation data 
obtained by MSP in patients. Lower percentages of MLLmu 
patients than MLLwt patients show promoter hypermethyla-
tion of BEX2, IGSF4 and TIMP3 (see also Additional file 3). C) 
Note that methylation of two out of three TSG (BEX2, 
IGSF4, TIMP3) is more frequent in MLLwt patients than in 
MLLmu patients.Molecular Cancer 2009, 8:86 http://www.molecular-cancer.com/content/8/1/86
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ogy domain, which binds CpG rich regions particularly
when these are unmethylated [23]. This domain is essen-
tial for target gene recognition and is required for transfor-
mation by MLL fusion proteins [24]. Therefore, the CXXC
domain might direct MLL to transcribed genes or possibly
protect CpG islands against methylation. The N-terminal
part of MLL has also been reported to bind menin [25].
MLL and menin are required for cellular transformation
and both proteins cooperatively regulate expression of the
genes p27Kip1 and p18Ink4c [25,26].
Thus, regulation of TSG expression and alterations of epi-
genetic functions of MLL fusion proteins are feasible con-
sequences of MLL  translocations, but whether the TSG
hypomethylation in MLLmu cell lines described by us is
the direct effect of MLL fusion proteins or whether the
hypomethylation is rather an indirect consequence,
remains to be resolved. For two reasons we favor the latter
explanation: MLLmu ALL cell lines do not show the TSG
methylation profile that is typical for MLLmu AML sug-
gesting that additional, tissue-specific factors play a role in
this context. Furthermore, ChIP-DNA mircroarrays did
not identify TIMP3 as target of wild-type MLL, the other
two genes not being tested [27]. Future studies will have
to provide evidence whether the MLL fusion proteins
show altered DNA binding specificities than the wild-type
protein allowing access to the promoters of the named
TSG.
Conclusion
We describe the conspicuous expression of TSG BEX2,
IGSF4 and TIMP3 in MLLmu AML cells. In MLLwt cell lines
these genes are silenced by promoter methylation. Tran-
scription could be reactivated by treatment with demeth-
ylating agents and HDAC inhibitors. In MLLmu AML cell
lines, constitutive expression of BEX2, IGSF4 and TIMP3
was accompanied by promoter hypomethylation. Ectopic
expression of MLL-ENL drove upregulation of Bex2 in a
Bisulfite sequencing of the IGSF4 promoter region Figure 4
Bisulfite sequencing of the IGSF4 promoter region. The IGSF4 promoter region (559 bp, 52 CpG sites) was sequenced 
after bisulfite conversion of DNA in two cell lines and selected AML patients. CpGs are represented as open dots (unmethyl-
ated) or filled dots (methylated). In MLLwt AML patients and in the MLLwt cell line U-937 clones with CpG methylation next to 
the transcriptional start site (TSS) were detected whereas no methylation was detectable in the MLLmu patient analyzed and in 
the MLLmu cell line THP-1. Note that CpG sites analyzed by the MS-MLPA probe (green) and MSP primers (red) are not iden-
tical.
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tamoxifen-inducible mouse model indicating that the
MLL fusion genes were responsible for upregulation of
TSG mRNA. Taken together, our results suggest that
hypomethylation of TSG characteristic of MLLmu AML
cells may be the consequence of MLL gene alterations,
including elements responsible for epigenetic regulation.
Methods
Human cell lines
The continuous cell lines were either taken from the stock
of the cell bank (DSMZ - German Collection of Microor-
ganisms and Cell Cultures) or were generously provided
by the original investigators. Detailed references and cul-
tivation protocols have been described previously [28,29].
The following cell lines were tested for TSG methylation:
(i) B-cell precursor (BCP) ALL-derived cell lines expressing
MLLwt: 380, 697, MHH-CALL-2, MHH-CALL-3, MHH-
CALL-4, NALM-6, SUP-B15; (ii) BCP ALL-derived cell
lines with MLLmu: KOCL-33 t(11;19), KOCL-45 t(4;11),
KOCL-58 t(4;11), KOPB-26 t(9;11), KOPN-8 t(11;19),
RS4;11 t(4;11), SEM t(4;11); (iii) AML-derived cell lines
with  MLLwt: AML-193 (M5), MML-1 (M1), MUTZ-3
(M4), OCI-AML5 (M4), SKM-1 (M5), U-937 (M5), YNH-
1 (M1); (iv) AML-derived cell lines with MLLmu: IMS-M1
(M5, t(9;11)), ML-2 (M4, t(6;11)), MOLM-13 (M5,
t(9;11)), MONO-MAC-6 (M5, t(9;11)), MV4;11 (M5,
t(4;11)), NOMO-1 (M5, t(9;11)), THP-1 (M5, t(9;11)).
Human tissue samples
After informed consent was given, bone marrow or
peripheral blood specimens were obtained during routine
clinical assessment of 40 AML patients. The collection of
patient samples for analysis of genetic changes was
approved by the local ethics committee. DNA extraction
was performed from unselected cells from bone marrow
or peripheral blood. The MLLwt/mu status of primary
samples was assessed with long-distance PCR analysis, as
described previously [30].
Methylation-specific multiplex ligation-dependent probe 
amplification assay
The MS-MLPA assay (ME001B; MRC-Holland, Amster-
dam, Netherlands) simultaneously detects copy number
changes and CpG methylation of the promoter regions of
24 different TSG. This semi-quantitative technique is
based on digestion of DNA with the methylation-sensitive
Inverse correlation between TSG methylation and expression Figure 5
Inverse correlation between TSG methylation and expression. Hypomethylation (yellow) parallels RNA expression 
(red) of BEX2, IGSF4 and TIMP3 in MLLmu AML. MLLwt AML cell lines show hypermethylation (light green) and transcriptional 
silencing (green) of these. In contrast, RARB expression is low (green) even in cell lines that carry the unmethylated promoter 
(yellow). Excluding RARB, TSG hypermethylation inversely correlated with gene transcription in 94% of the cases. TSG methyl-
ation status is shown as determined by MS-MLPA (see Additional file 1). Gene expression was assessed in triplicates by quanti-
tative real-time PCR (RT-PCR) analysis. For BEX2, IGSF4 and TIMP3, cell line IMS-M1 was applied as calibrator; for RARB, 
expression levels in cell line 697 were set as 1. Cell lines that reached relative expression levels ≥ 0.05 were considered posi-
tive (red).
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restriction enzyme HhaI (Fermentas, St. Leon-Rot, Ger-
many) and a subsequent multiplex PCR followed by frag-
ment analysis via capillary electrophoresis [31]. MS-MLPA
data were analysed using a Microsoft Excel spreadsheet
designed specifically for the ME001B assay. Levels of
methylation were calculated by comparing the relative
peak area of the HhaI digested ligation product with the
corresponding ligation product from the undigested sam-
ple. Peak areas were normalised relative to neighbouring
control ligation products prior to comparison as recom-
mended by MRC-Holland. The spreadsheet for the analy-
sis of the ME001B kit is freely available for download and
use on the National Genetics Reference Laboratory web-
site at http://www.ngrl.org.uk/Manchester/mlpa
pubs.html. For assessment of BEX2  promoter methyla-
tion, HhaI-digested and undigested DNA was used as tem-
plate for subsequent quantitative real-time PCR using
SYBR GREEN PCR Master Mix (Applied Biosystems, Foster
City, CA, USA) in a 7500 Applied Biosystems real-time
PCR system. The sequence flanked by primer pair A lacked
HhaI sites, and was used as endogenous control. Sequence
amplified by primer pair B contained two HhaI sites. The
percentage of non-cleaved and thus methylated template
in comparison to the undigested sample was calculated
using the ΔΔCt-method. BEX2 A forward: 5'-GGT TGG
TGA GAA GGA GGG TG-3'; BEX2 A reverse: 5'-GAG ACA
CGA GTG ACG ACT GCA-3'; BEX2  B forward: 5'-TGG
AGA GGA CGG AGA TGA GTG-3'; BEX2 B reverse: 5'-CAC
CCT CCT TCT CAC CAA CC-3'. Methylation was scored
positive when the calculated methylation percentage was
≥ 10%.
Methylation-specific polymerase chain reaction (MSP)
Bisulfite conversion of DNA was performed as described
by the supplier (Active Motif, Rixensart, Belgium). For
detecting TSG promoter methylation, we performed
nested PCR with first round primers amplifying converted
DNA independently of the methylation status (bisulfite-
specific PCR), while second round primers for M- and U-
PCR specifically recognized the methylated or unmethyl-
ated versions of the promoter. PCR products of the initial
bisulfite-specific PCR were diluted 1:100 for subsequent
M- and U-PCR. PCR conditions and primer sequences are
Table 1: Effects of Aza and TSA on TSG expression in MLLwt 
AML cell lines. 
cell line treatment TSG
BEX2 IGSF4 TIMP3
AML-193 TSA - - +
Aza ++ ++ +++
Aza + TSA ++ ++ +++
SKM-1 TSA (+) + +
Aza - (+) +
Aza + TSA +++ +
U-937 TSA - ++ +
Aza - +++ +++
Aza + TSA - +++ +++
Induction of TSG expression by Aza (5 μM, 4 d) and TSA (2 μM, 1 d) 
when compared to untreated control cells: - < 2-fold, + ≥ 2-fold; ++ ≥ 
10-fold, +++ ≥ 100-fold gene expression. Expression levels were 
determined by quantitative real-time PCR. Note that cell line SKM-1 
shows hypomethylation and expression of IGSF4 and TIMP3 (Fig. 5). 
Experiments were performed at least twice. Brackets: effect variable.
MLL fusion proteins regulate Bex2 expression Figure 6
MLL fusion proteins regulate Bex2 expression. In presence of 4-OHT (100 nM) MLL-ENL-ERtm mouse cell lines 
expressed MLL-ENL and Bex2. Withdrawal of 4-OHT for seven to nine days induced downregulation of MLL-ENL and suppres-
sion of Bex2 transcription. Bex2 expression levels with standard deviations were determined in two different MLL-ENL-ERtm 
cell line clones by quantitative real-time PCR analysis.
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listed in Additional file 5. Epitect PCR Control DNA (Qia-
gen, Hilden, Germany) was used as control for methyl-
ated and unmethylated templates.
Bisulfite sequencing
To confirm methylation status of the IGSF4  promoter,
DNA of cell lines and AML patients was bisulfite con-
verted according to the manufacturer's instructions
(Active Motif). Subsequently, amplification of the IGSF4
promoter region (559 bp) was performed using primers
IGSF4 BSP fwd and IGSF4 BSP rev, specifically binding
bisulfite converted DNA (for primer sequence and PCR
conditions see Additional file 5). Resulting IGSF4 frag-
ments were purified, cloned into pGEM-T Easy vector
(Promega, Madison, WI, USA) and sequenced. Sequences
were evaluated using BiQ Analyzer http://biq-ana
lyzer.bioinf.mpi-sb.mpg.de and had to conform to at least
90% bisulfite conversion rate. In addition, identical
clones were excluded from the analysis.
Expression of tumor suppressor genes
Quantitative PCR was performed on a 7500 Applied Bio-
systems (Darmstadt, Germany) real-time PCR system
using the manufacturer's protocol. RNA was prepared
using the Trizol reagent (Invitrogen, Karlsruhe, Germany).
For mRNA quantification, reverse transcription was per-
formed using the SuperScript II reverse transcriptase kit
(Invitrogen). TaqMan probes (Applied Biosystems) were
used to quantify human BEX2 (Hs 00218464m1), IGSF4
(Hs 00204937m1), RARB (Hs 00233407m1) and TIMP3
(Hs 00927216m1) expression levels with TBP as endog-
enous control. Expression of mouse Bex2  was assessed
using the SYBR GREEN PCR Master Mix (Applied Biosys-
tems) with Tbp as internal control. Bex2 forward: 5'-GCG
AGC GGG ACA GAT TGA C-3'; Bex2 reverse: 5'-TCC ATT
TCT CCT GGG CCT ATC-3'. Tbp forward: 5'-ACC AGA
ACA ACA GCC TTC CAC-3'; Tbp reverse: 5'-TGC CGT AAG
GCA TCA TTG GAC-3'. Relative expression levels were cal-
culated using the ΔΔCt-method.
Induction of MLL-ENL
Mouse bone marrow cell lines MLL-ENL-ERtm 1 and 3
were maintained in RPMI 1640 medium supplemented
with 10% FBS (Sigma, Taufkirchen, Germany), IL-3 (5 ng/
ml), GM-CSF (5 ng/ml), IL-6 (5 ng/ml), SCF (50 ng/ml)
and 4-OHT (100 nM). Murine cytokines were obtained
from Richter-Helm (BioLogics, Hamburg, Germany) and
4-OHT was purchased from Sigma. 4-OHT releases MLL-
ENL from a heat-shock protein complex thereby activating
the fusion protein [21]. Note that MLL-ENL is essentially
required for the continuous proliferation of this cell line.
Treatment with demethylating agents and inhibitors of 
histone deacetylases
Aza (Sigma) was used to verify the effect of methylation
on expression of TSG. The HDAC inhibitor TSA (Sigma)
was applied for testing the role of histone acetylation for
TSG expression. Cells were seeded at a cell density of 5 ×
105 cells/ml, Aza was added at a final concentration of 5
μM. Control cells were treated with 0.05% DMSO. After 2
d, half of the medium was replenished with medium
with/without Aza (5 μM). TSA (2 μM final concentration)
was added for the last 24 h of cultivation. After 4 d, cells
were harvested to prepare RNA and protein.
Histone purification and Western blot analysis
Histones were purified according to the protocol of the
supplier (Active Motif). Then, 3.3 μg or 10 μg protein were
separated by electrophoresis (15% SDS gels) to detect his-
tones and acetylated histones, respectively. Anti acetyl his-
tone H4K12 antiserum was obtained from Biomol/
Upstate (Hamburg, Germany), anti histone H4 mono-
clonal Ab was purchased from Abcam (Cambridge,
United Kingdom). Specific bands on nitrocellulose mem-
branes were visualized with the biotin/streptavidin-horse-
radish peroxidase system (Amersham, Freiburg,
Germany) in combination with the "Renaissance Western
Blot Chemoluminescence Reagent" protocol (DuPont,
Bad Homburg, Germany).
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Additional file 2
MSP analyses of BEX2, IGSF4 and TIMP3 in AML cell lines. Methyl-
ation status of BEX2, IGSF4 and TIMP3 were determined in MLLwt and 
MLLmu AML cell lines by MSP to control methylation status as deter-
mined by MS-MLPA. Results for M- and U-PCR are shown as well as the 
methylation status according to MS-MLPA. Performance of MS-MLPA as 
a classification system for methylated or unmethylated TSG was evaluated 
using a confusion matrix. Overall, the results of the techniques were in 
good concordance with an accuracy of 0.83. In detail, accuracy was 0.86 
for BEX2, 0.93 for IGSF4 and 0.71 for TIMP3.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
4598-8-86-S2.JPEG]
Additional file 3
Methylation analyses in primary AML samples. Results of promoter 
methylation analysis according to MSP of BEX2, IGSF4, RARB and 
TIMP3 are shown for MLLmu and MLLwt AML patients
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Additional file 4
Activating histone modifications induced by TSA. TSA effected acetyla-
tion of histone H4K12, as assessed by Western blot analysis. Aza treat-
ment was not alone sufficient to induce histone H4K12 acetylation. 
MLLwt cell lines AML-193, SKM-1 and U-937 were treated with TSA (2 
μM, 1 d), Aza (5 μM, 4 d) or a combination of both reagents.
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